Global Age Related Macular Degeneration

Age Related Macular Degeneration Comprehensive Study by Type (Wet AMD, Dry AMD), Drugs (Lucentis, Eylea, Avastin, Others), Route of Administration (Intravenous, Intravitreal) Players and Region - Global Market Outlook to 2028

Age Related Macular Degeneration Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The age-related macular degeneration (AMD) is a common eye complaint and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a minor spot near the center of the retina and the portion of the eye needed for sharp, central vision, which lets a person see objects that are straight ahead. In some people, AMD develops so slowly that vision loss does not occur for a long time. In others, the disease advancements faster and may lead to a loss of vision in one or both eyes. As AMD progresses, a blurred area near the center of vision is a general symptom.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledNovartis Ag (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Pfizer Inc. (United States), Regeneron Pharmaceutical, Inc. (United States), Acucela (United States), Neurotech Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan) and Synthetic Biologics Inc. (United States)


This growth is primarily driven by Increase in Aging Population Worldwide and Rising Pipeline Drugs for Age-Related Macular Degeneration.

Globally, a noticeable market trend is evident Increasing Awareness about Age-Related Macular Degeneration Major Players, such as Novartis Ag (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Pfizer Inc. (United States), Regeneron Pharmaceutical, Inc. (United States), Acucela (United States), Neurotech Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan) and Synthetic Biologics Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On July 1, 2019 - Pfizer Inc. has announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.

Influencing Trend:
Increasing Awareness about Age-Related Macular Degeneration

Market Growth Drivers:
Increase in Aging Population Worldwide and Rising Pipeline Drugs for Age-Related Macular Degeneration

Challenges:
Growing Off Label Use

Restraints:
High Cost of AMD Treatment

Opportunities:
Increasing Incidence of Lifestyle Associated Diseases

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Age Related Macular Degeneration Market
- Analysis about New Entrants in Age Related Macular Degeneration Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Age Related Macular Degeneration Study Sheds Light on
— The Age Related Macular Degeneration Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Age Related Macular Degeneration industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Age Related Macular Degeneration industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Wet AMD
  • Dry AMD
By Drugs
  • Lucentis
  • Eylea
  • Avastin
  • Others

By Route of Administration
  • Intravenous
  • Intravitreal

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Aging Population Worldwide
      • 3.2.2. Rising Pipeline Drugs for Age-Related Macular Degeneration
    • 3.3. Market Challenges
      • 3.3.1. Growing Off Label Use
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness about Age-Related Macular Degeneration
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Age Related Macular Degeneration, by Type, Drugs, Route of Administration and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Age Related Macular Degeneration (Value)
      • 5.2.1. Global Age Related Macular Degeneration by: Type (Value)
        • 5.2.1.1. Wet AMD
        • 5.2.1.2. Dry AMD
      • 5.2.2. Global Age Related Macular Degeneration by: Drugs (Value)
        • 5.2.2.1. Lucentis
        • 5.2.2.2. Eylea
        • 5.2.2.3. Avastin
        • 5.2.2.4. Others
      • 5.2.3. Global Age Related Macular Degeneration by: Route of Administration (Value)
        • 5.2.3.1. Intravenous
        • 5.2.3.2. Intravitreal
      • 5.2.4. Global Age Related Macular Degeneration Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Age Related Macular Degeneration (Price)
      • 5.3.1. Global Age Related Macular Degeneration by: Type (Price)
  • 6. Age Related Macular Degeneration: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis Ag (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Regeneron Pharmaceutical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Acucela (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neurotech Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Santen Pharmaceutical Co. Ltd. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Synthetic Biologics Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Age Related Macular Degeneration Sale, by Type, Drugs, Route of Administration and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Age Related Macular Degeneration (Value)
      • 7.2.1. Global Age Related Macular Degeneration by: Type (Value)
        • 7.2.1.1. Wet AMD
        • 7.2.1.2. Dry AMD
      • 7.2.2. Global Age Related Macular Degeneration by: Drugs (Value)
        • 7.2.2.1. Lucentis
        • 7.2.2.2. Eylea
        • 7.2.2.3. Avastin
        • 7.2.2.4. Others
      • 7.2.3. Global Age Related Macular Degeneration by: Route of Administration (Value)
        • 7.2.3.1. Intravenous
        • 7.2.3.2. Intravitreal
      • 7.2.4. Global Age Related Macular Degeneration Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Age Related Macular Degeneration (Price)
      • 7.3.1. Global Age Related Macular Degeneration by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Age Related Macular Degeneration: by Type(USD Million)
  • Table 2. Age Related Macular Degeneration Wet AMD , by Region USD Million (2017-2022)
  • Table 3. Age Related Macular Degeneration Dry AMD , by Region USD Million (2017-2022)
  • Table 4. Age Related Macular Degeneration: by Drugs(USD Million)
  • Table 5. Age Related Macular Degeneration Lucentis , by Region USD Million (2017-2022)
  • Table 6. Age Related Macular Degeneration Eylea , by Region USD Million (2017-2022)
  • Table 7. Age Related Macular Degeneration Avastin , by Region USD Million (2017-2022)
  • Table 8. Age Related Macular Degeneration Others , by Region USD Million (2017-2022)
  • Table 9. Age Related Macular Degeneration: by Route of Administration(USD Million)
  • Table 10. Age Related Macular Degeneration Intravenous , by Region USD Million (2017-2022)
  • Table 11. Age Related Macular Degeneration Intravitreal , by Region USD Million (2017-2022)
  • Table 12. South America Age Related Macular Degeneration, by Country USD Million (2017-2022)
  • Table 13. South America Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 14. South America Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 15. South America Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 16. Brazil Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 17. Brazil Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 18. Brazil Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 19. Argentina Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 20. Argentina Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 21. Argentina Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 22. Rest of South America Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 23. Rest of South America Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 24. Rest of South America Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 25. Asia Pacific Age Related Macular Degeneration, by Country USD Million (2017-2022)
  • Table 26. Asia Pacific Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 27. Asia Pacific Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 28. Asia Pacific Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 29. China Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 30. China Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 31. China Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 32. Japan Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 33. Japan Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 34. Japan Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 35. India Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 36. India Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 37. India Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 38. South Korea Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 39. South Korea Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 40. South Korea Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 41. Taiwan Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 42. Taiwan Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 43. Taiwan Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 44. Australia Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 45. Australia Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 46. Australia Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 50. Europe Age Related Macular Degeneration, by Country USD Million (2017-2022)
  • Table 51. Europe Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 52. Europe Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 53. Europe Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 54. Germany Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 55. Germany Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 56. Germany Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 57. France Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 58. France Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 59. France Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 60. Italy Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 61. Italy Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 62. Italy Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 63. United Kingdom Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 64. United Kingdom Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 65. United Kingdom Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 66. Netherlands Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 67. Netherlands Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 68. Netherlands Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 69. Rest of Europe Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 70. Rest of Europe Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 71. Rest of Europe Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 72. MEA Age Related Macular Degeneration, by Country USD Million (2017-2022)
  • Table 73. MEA Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 74. MEA Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 75. MEA Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 76. Middle East Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 77. Middle East Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 78. Middle East Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 79. Africa Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 80. Africa Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 81. Africa Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 82. North America Age Related Macular Degeneration, by Country USD Million (2017-2022)
  • Table 83. North America Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 84. North America Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 85. North America Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 86. United States Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 87. United States Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 88. United States Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 89. Canada Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 90. Canada Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 91. Canada Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 92. Mexico Age Related Macular Degeneration, by Type USD Million (2017-2022)
  • Table 93. Mexico Age Related Macular Degeneration, by Drugs USD Million (2017-2022)
  • Table 94. Mexico Age Related Macular Degeneration, by Route of Administration USD Million (2017-2022)
  • Table 95. Age Related Macular Degeneration: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Age Related Macular Degeneration: by Type(USD Million)
  • Table 107. Age Related Macular Degeneration Wet AMD , by Region USD Million (2023-2028)
  • Table 108. Age Related Macular Degeneration Dry AMD , by Region USD Million (2023-2028)
  • Table 109. Age Related Macular Degeneration: by Drugs(USD Million)
  • Table 110. Age Related Macular Degeneration Lucentis , by Region USD Million (2023-2028)
  • Table 111. Age Related Macular Degeneration Eylea , by Region USD Million (2023-2028)
  • Table 112. Age Related Macular Degeneration Avastin , by Region USD Million (2023-2028)
  • Table 113. Age Related Macular Degeneration Others , by Region USD Million (2023-2028)
  • Table 114. Age Related Macular Degeneration: by Route of Administration(USD Million)
  • Table 115. Age Related Macular Degeneration Intravenous , by Region USD Million (2023-2028)
  • Table 116. Age Related Macular Degeneration Intravitreal , by Region USD Million (2023-2028)
  • Table 117. South America Age Related Macular Degeneration, by Country USD Million (2023-2028)
  • Table 118. South America Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 119. South America Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 120. South America Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 121. Brazil Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 122. Brazil Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 123. Brazil Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 124. Argentina Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 125. Argentina Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 126. Argentina Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 127. Rest of South America Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 128. Rest of South America Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 129. Rest of South America Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 130. Asia Pacific Age Related Macular Degeneration, by Country USD Million (2023-2028)
  • Table 131. Asia Pacific Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 132. Asia Pacific Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 133. Asia Pacific Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 134. China Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 135. China Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 136. China Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 137. Japan Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 138. Japan Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 139. Japan Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 140. India Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 141. India Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 142. India Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 143. South Korea Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 144. South Korea Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 145. South Korea Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 146. Taiwan Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 147. Taiwan Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 148. Taiwan Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 149. Australia Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 150. Australia Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 151. Australia Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 152. Rest of Asia-Pacific Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 153. Rest of Asia-Pacific Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 154. Rest of Asia-Pacific Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 155. Europe Age Related Macular Degeneration, by Country USD Million (2023-2028)
  • Table 156. Europe Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 157. Europe Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 158. Europe Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 159. Germany Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 160. Germany Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 161. Germany Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 162. France Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 163. France Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 164. France Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 165. Italy Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 166. Italy Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 167. Italy Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 168. United Kingdom Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 169. United Kingdom Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 170. United Kingdom Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 171. Netherlands Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 172. Netherlands Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 173. Netherlands Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 174. Rest of Europe Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 175. Rest of Europe Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 176. Rest of Europe Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 177. MEA Age Related Macular Degeneration, by Country USD Million (2023-2028)
  • Table 178. MEA Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 179. MEA Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 180. MEA Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 181. Middle East Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 182. Middle East Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 183. Middle East Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 184. Africa Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 185. Africa Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 186. Africa Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 187. North America Age Related Macular Degeneration, by Country USD Million (2023-2028)
  • Table 188. North America Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 189. North America Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 190. North America Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 191. United States Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 192. United States Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 193. United States Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 194. Canada Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 195. Canada Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 196. Canada Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 197. Mexico Age Related Macular Degeneration, by Type USD Million (2023-2028)
  • Table 198. Mexico Age Related Macular Degeneration, by Drugs USD Million (2023-2028)
  • Table 199. Mexico Age Related Macular Degeneration, by Route of Administration USD Million (2023-2028)
  • Table 200. Age Related Macular Degeneration: by Type(USD/Units)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Age Related Macular Degeneration: by Type USD Million (2017-2022)
  • Figure 5. Global Age Related Macular Degeneration: by Drugs USD Million (2017-2022)
  • Figure 6. Global Age Related Macular Degeneration: by Route of Administration USD Million (2017-2022)
  • Figure 7. South America Age Related Macular Degeneration Share (%), by Country
  • Figure 8. Asia Pacific Age Related Macular Degeneration Share (%), by Country
  • Figure 9. Europe Age Related Macular Degeneration Share (%), by Country
  • Figure 10. MEA Age Related Macular Degeneration Share (%), by Country
  • Figure 11. North America Age Related Macular Degeneration Share (%), by Country
  • Figure 12. Global Age Related Macular Degeneration: by Type USD/Units (2017-2022)
  • Figure 13. Global Age Related Macular Degeneration share by Players 2022 (%)
  • Figure 14. Global Age Related Macular Degeneration share by Players (Top 3) 2022(%)
  • Figure 15. Global Age Related Macular Degeneration share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis Ag (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis Ag (Switzerland) Revenue: by Geography 2022
  • Figure 19. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2022
  • Figure 21. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Regeneron Pharmaceutical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Regeneron Pharmaceutical, Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Acucela (United States) Revenue, Net Income and Gross profit
  • Figure 28. Acucela (United States) Revenue: by Geography 2022
  • Figure 29. Neurotech Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Neurotech Pharmaceuticals, Inc. (United States) Revenue: by Geography 2022
  • Figure 31. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 33. Santen Pharmaceutical Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Santen Pharmaceutical Co. Ltd. (Japan) Revenue: by Geography 2022
  • Figure 35. Synthetic Biologics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Synthetic Biologics Inc. (United States) Revenue: by Geography 2022
  • Figure 37. Global Age Related Macular Degeneration: by Type USD Million (2023-2028)
  • Figure 38. Global Age Related Macular Degeneration: by Drugs USD Million (2023-2028)
  • Figure 39. Global Age Related Macular Degeneration: by Route of Administration USD Million (2023-2028)
  • Figure 40. South America Age Related Macular Degeneration Share (%), by Country
  • Figure 41. Asia Pacific Age Related Macular Degeneration Share (%), by Country
  • Figure 42. Europe Age Related Macular Degeneration Share (%), by Country
  • Figure 43. MEA Age Related Macular Degeneration Share (%), by Country
  • Figure 44. North America Age Related Macular Degeneration Share (%), by Country
  • Figure 45. Global Age Related Macular Degeneration: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Novartis Ag (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bayer AG (Germany)
  • Pfizer Inc. (United States)
  • Regeneron Pharmaceutical, Inc. (United States)
  • Acucela (United States)
  • Neurotech Pharmaceuticals, Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Santen Pharmaceutical Co. Ltd. (Japan)
  • Synthetic Biologics Inc. (United States)
Additional players considered in the study are as follows:
Stemcells Inc. (United States) , Alimera Sciences, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 216 Pages 92 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Age Related Macular Degeneration Quantitative research analysis
Global Age Related Macular Degeneration Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Age Related Macular Degeneration market are Novartis Ag (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Pfizer Inc. (United States), Regeneron Pharmaceutical, Inc. (United States), Acucela (United States), Neurotech Pharmaceuticals, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Santen Pharmaceutical Co. Ltd. (Japan) and Synthetic Biologics Inc. (United States), to name a few.
is dominating the Age Related Macular Degeneration Market.
"Growing Off Label Use" is seen as one of the major challenges by many Industry Players of Age Related Macular Degeneration Market
The Age Related Macular Degeneration market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Age Related Macular Degeneration market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Age Related Macular Degeneration Report?

Have a Query? Click Here

Other Related Reports

Diabetic Nephropathy Comprehensive Study by Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Treatment (Medication, Kidney Dialysis, Kidney Transplant), Stages (Microalbuminuria ...
$ 3750
Negative Pressure Wound Therapy Comprehensive Study by Type (Standalone NPWT Devices, Single use Disposable NPWT Devices, Portable NPWT Devices, NPWT Accessories (Canister)), Application (Hospital, C...
$ 3350
Chitosan Gel Comprehensive Study by Type (Industrial Grade, Pharmaceutical Grade, Others), Application (Surgical, Gynecological Diseases, Hemorrhoid Disease, Others), Distribution Channel (Hospital P...
$ 3450
Rosacea Treatment Comprehensive Study by Type (Erythematotelangiectatic Rosacea, Papulopustular Rosacea, Ocular Rosacea, Phymatous Rosacea), Drugs (Rhofade, Mirvaso, Oracea, Others), Route of Adminis...
$ 3750
Hadron Therapy Comprehensive Study by Type (Electron Beam, Neutron Beam, Alpha Particle Beam, Proton Beam, Carbon Ion Beam, Beta Particle Beam), Application (Treatment Applications, Research Applicat...
$ 3750
Adenomyosis Treatment Comprehensive Study by Type (Focal, Adenomyoma, Diffuse, Others), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Treatment (Anti-inflammatory Drugs (ibup...
$ 3750